Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Common Equity (2019 - 2025)

Keros Therapeutics filings provide 7 years of Common Equity readings, the most recent being $303.1 million for Q4 2025.

  • On a quarterly basis, Common Equity fell 46.96% to $303.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $303.1 million, a 46.96% decrease, with the full-year FY2025 number at $303.1 million, down 46.96% from a year prior.
  • Common Equity hit $303.1 million in Q4 2025 for Keros Therapeutics, down from $703.6 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $728.9 million in Q1 2025 to a low of $211.2 million in Q2 2022.
  • Median Common Equity over the past 5 years was $314.7 million (2023), compared with a mean of $381.5 million.
  • Biggest five-year swings in Common Equity: skyrocketed 1098.8% in 2021 and later tumbled 46.96% in 2025.
  • Keros Therapeutics' Common Equity stood at $243.2 million in 2021, then grew by 14.08% to $277.4 million in 2022, then grew by 19.75% to $332.2 million in 2023, then soared by 72.04% to $571.6 million in 2024, then crashed by 46.96% to $303.1 million in 2025.
  • The last three reported values for Common Equity were $303.1 million (Q4 2025), $703.6 million (Q3 2025), and $706.7 million (Q2 2025) per Business Quant data.